Evidence map›Paper›PMID 38203500›Full record

ArticleInternational journal of molecular sciences2023

Studying the Roles of the Renin-Angiotensin System in Accelerating the Disease of High-Fat-Diet-Induced Diabetic Nephropathy in a db/db and ACE2 Double-Gene-Knockout Mouse Model.

Cheng-Yi Chen, Meng-Wei Lin, Xing-Yang Xie, Cheng-Han Lin, Chung-Wei Yang, Pei-Ching Wu, Dung-Huan Liu, Chih-Jen Wu, Chih-Sheng Lin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cheng-Yi ChenDivision of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Hsinchu 300, Taiwan.ORCID 0000-0003-3634-9661
Meng-Wei LinDepartment of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Xing-Yang XieDepartment of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Cheng-Han LinDepartment of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Chung-Wei YangDivision of Nephrology, Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu 300, Taiwan.
Pei-Ching WuDoctoral Degree Program of Biomedical Science and Engineering, College of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Dung-Huan LiuDoctoral Degree Program of Biomedical Science and Engineering, College of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.
Chih-Jen WuDivision of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei 100, Taiwan.
Chih-Sheng LinDepartment of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.ORCID 0000-0003-1140-7933
National Yang Ming Chiao Tung University · TWMackay Memorial Hospital · TW

Funding

National Science and Technology Council 110-2312-B-A49-001-MY3National Science and Technology Council 112-2321-B-A49-005National Science and Technology Council 112-2321-B-A49-018National Science and Technology Council 112-2811-B-A49-501National Science and Technology Council 112-2811-B-A49-503
6 · The paper itself

Abstract

Diabetic nephropathy (DN) is a crucial metabolic health problem. The renin-angiotensin system (RAS) is well known to play an important role in DN. Abnormal RAS activity can cause the over-accumulation of angiotensin II (Ang II). Angiotensin-converting enzyme inhibitor (ACEI) administration has been proposed as a therapy, but previous studies have also indicated that chymase, the enzyme that hydrolyzes angiotensin I to Ang II in an ACE-independent pathway, may play an important role in the progression of DN. Therefore, this study established a model of severe DN progression in a db/db and ACE2 KO mouse model (db and ACE2 double-gene-knockout mice) to explore the roles of RAS factors in DNA and changes in their activity after short-term (only 4 weeks) feeding of a high-fat diet (HFD) to 8-week-old mice. The results indicate that FD-fed db/db and ACE2 KO mice fed an HFD represent a good model for investigating the role of RAS in DN. An HFD promotes the activation of MAPK, including p-JNK and p-p38, as well as the RAS signaling pathway, leading to renal damage in mice. Blocking Ang II/AT1R could alleviate the progression of DN after administration of ACEI or chymase inhibitor (CI). Both ACE and chymase are highly involved in Ang II generation in HFD-induced DN; therefore, ACEI and CI are potential treatments for DN.

Indexed as

Diabetes MellitusDiabetic NephropathiesPeptide HormonesAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin IIAnimalsAntiviral AgentsChymasesDiet, High-FatDisease Models, AnimalMiceMice, KnockoutRenin-Angiotensin SystemSerine ProteasesAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin IIAntiviral AgentsChymasesPeptide HormonesSerine Proteasesangiotensin converting enzyme II (ACE2)chymasediabetic nephropathyhigh-fat-dietrenin angiotensin system

Identifiers

PMID38203500
PMCPMC10779113
OpenAlexW4390232897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.